1. Home
  2. RBCAA vs AGIO Comparison

RBCAA vs AGIO Comparison

Compare RBCAA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RBCAA
  • AGIO
  • Stock Information
  • Founded
  • RBCAA 1974
  • AGIO 2007
  • Country
  • RBCAA United States
  • AGIO United States
  • Employees
  • RBCAA N/A
  • AGIO N/A
  • Industry
  • RBCAA Major Banks
  • AGIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • RBCAA Finance
  • AGIO Health Care
  • Exchange
  • RBCAA Nasdaq
  • AGIO Nasdaq
  • Market Cap
  • RBCAA 1.3B
  • AGIO 1.4B
  • IPO Year
  • RBCAA 1998
  • AGIO 2013
  • Fundamental
  • Price
  • RBCAA $68.64
  • AGIO $36.21
  • Analyst Decision
  • RBCAA Hold
  • AGIO Buy
  • Analyst Count
  • RBCAA 1
  • AGIO 6
  • Target Price
  • RBCAA N/A
  • AGIO $57.40
  • AVG Volume (30 Days)
  • RBCAA 38.7K
  • AGIO 1.1M
  • Earning Date
  • RBCAA 07-18-2025
  • AGIO 07-31-2025
  • Dividend Yield
  • RBCAA 2.63%
  • AGIO N/A
  • EPS Growth
  • RBCAA 27.68
  • AGIO N/A
  • EPS
  • RBCAA 6.28
  • AGIO 11.13
  • Revenue
  • RBCAA $369,212,000.00
  • AGIO $40,875,000.00
  • Revenue This Year
  • RBCAA $14.17
  • AGIO $18.94
  • Revenue Next Year
  • RBCAA $10.87
  • AGIO $201.70
  • P/E Ratio
  • RBCAA $10.90
  • AGIO $3.25
  • Revenue Growth
  • RBCAA 16.32
  • AGIO 30.57
  • 52 Week Low
  • RBCAA $54.88
  • AGIO $23.42
  • 52 Week High
  • RBCAA $80.68
  • AGIO $62.58
  • Technical
  • Relative Strength Index (RSI)
  • RBCAA 36.46
  • AGIO 45.37
  • Support Level
  • RBCAA $66.82
  • AGIO $26.75
  • Resistance Level
  • RBCAA $69.05
  • AGIO $38.43
  • Average True Range (ATR)
  • RBCAA 1.70
  • AGIO 2.46
  • MACD
  • RBCAA -0.76
  • AGIO -0.64
  • Stochastic Oscillator
  • RBCAA 16.37
  • AGIO 63.11

About RBCAA Republic Bancorp Inc.

Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: